1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Material disclosure
Amended material disclosure
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
News, Material Contracts
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities